RxDoctor Payments Data

Jessie Rollins, DO

Family Medicine · Riverside, CANPI 1174825053

Payments from drug & device makers

$819in general payments, 2019–2025

Across 24 payments — averaging $34.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$182
  • AbbVie$153
  • Novo Nordisk$125
  • Dynavax Technologies Corporation$123
  • Amarin Pharma, Inc.$104
  • Lilly USA, LLC$55
  • plus $79 from 3 others

What the payments were for

  • Food & beverage$819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$819 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$66,753
Medicare patients
160
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$135,096
OzempicSemaglutide109$113,870
JardianceEmpagliflozin64$70,194
JanuviaSitagliptin Phosphate73$58,796
TrulicityDulaglutide36$40,097
XareltoRivaroxaban47$39,836
FarxigaDapagliflozin Propanediol39$36,028
EntrestoSacubitril/Valsartan13$16,516
MounjaroTirzepatide13$13,092
MyrbetriqMirabegron13$11,568
RybelsusSemaglutide12$11,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$11,178
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$10,838
KerendiaFinerenone12$10,189
Tresiba Flextouch U-200Insulin Degludec14$9,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$125$125,285121 claims
Lilly USA, LLCTrulicity, Mounjaro$55$53,18949 claims
Johnson & JohnsonXarelto$182$39,83647 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$51$29,45543 claims
AbbVieSynthroid$153$2,77336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →